Illumina, Inc.

Illumina, Inc., a San Diego-based manufacturer of genetic sequencing instruments, reagents, consumables, and bioinformatics software, operates as a prime contractor across 134 federal agencies, with 8,641 prime awards (100% of contract and grant portfolio) and minimal subcontractor engagement. The company competes on full-and-open basis across all awards; no set-aside categories are present in the footprint. Illumina is a for-profit corporation with two named subsidiaries, Epicentre Technologies Corporation and Affomix Corporation.

Illumina's core federal capability is the design, manufacture, and deployment of next-generation DNA and RNA sequencing platforms (NextSeq, NovaSeq, MiSeq, iSeq lines), along with proprietary reagent kits, library preparation materials, genotyping arrays, DRAGEN bioinformatics processors and software, and full-lifecycle maintenance and support services. Representative prime awards include a $1.999 billion definitive contract with the Department of Veterans Affairs Technology Acquisition Center (September 2025) for eight DRAGEN Servers v4 capable of processing whole genome sequencing and multi-omics analysis at 2 million gigabytes annual throughput; a $90 million single-award IDIQ with the National Human Genome Research Institute (May 2026, through May 2031) for Illumina reagents and consumables under Executive Order 14398; a $45 million USDA indefinite delivery contract (1232SA25D0004, through June 2030) providing comprehensive access to Illumina's full sequencing platform portfolio across Agricultural Research Service, Plant Protection and Quarantine, Veterinary Services, and Food Safety and Inspection Service; an $871 thousand FDA delivery order (September 2026) for five MiSeq i100 Plus genomic sequencing systems supporting whole genome sequencing for bacterial and viral organisms; and a $1.33 million NIH delivery order (May 2026) for Illumina kits supporting the NIH Intramural Sequencing Center (NISC). The SCI dataset shows minimal service-contract reporting—$402 thousand invoiced across FY2022–FY2025—with median government-paid rates around $3,834/hr and senior labor pricing through $8,128/hr, reflecting that Illumina's federal revenue footprint is dominated by product sales and maintenance rather than labor-billed services.

Customer concentration is heavily weighted toward HHS agencies. The top five customers by award count (covering 32% of all awards) are the National Cancer Institute (641 awards, $43.9 million), National Institute of Allergy and Infectious Diseases (573 awards, $32 million), National Human Genome Research Institute (560 awards, $137.5 million), Food and Drug Administration (522 awards, $133.6 million), and National Heart Lung and Blood Institute (476 awards, $273.7 million combined potential value). The same five agencies dominate potential-value rankings and account for 51% of combined potential value across all awards, indicating high customer concentration and alignment between volume and dollar value. The National Human Genome Research Institute ($137.5 million), Food and Drug Administration ($133.6 million), and National Heart Lung and Blood Institute ($273.7 million) anchor the largest single-customer relationships by dollar magnitude.

Illumina sits on five principal parent vehicles: an Indefinite Delivery Contract HHSN268201500004I with 1,277 task orders worth $80.8 million; an Indefinite Delivery Contract 75N92020D00022 with 1,051 task orders worth $89 million; an Indefinite Delivery Contract HHSN268201000003I with 653 task orders worth $34.7 million; a Blanket Purchase Agreement AG32SCB140005 with 500 task orders worth $21.6 million; and an Indefinite Delivery Contract 1232SA20D0001 with 372 task orders worth $31 million. These vehicles enable rapid procurement of consumables and maintenance across NIH institutes, USDA divisions, and other civilian agencies without individual competitive competitions.

Activity has declined year over year: 508 awards in 2022, 417 in 2023, 374 in 2024, 324 in 2025, and 167 through 2026 (partial year). The combined potential value across all 8,680 awards is $1.22 billion, with $675 million obligated (55% of potential). Within the next 24 months, 147 awards (combined potential value $21.3 million) reach ultimate completion, presenting recompete exposure for competitors and renewal opportunity for Illumina across maintenance agreements and consumables orders.

Illumina operates almost exclusively as a prime (8,641 of 8,680 awards), with minimal sub-award activity (39 awards, 0% of portfolio). The sub-award footprint shows two named primes: Battelle Memorial Institute (received Illumina NovaSeq 6000 S4 reagent kits and NextSeq 550 support-plan sub-awards for NIEHS toxicology and DHS biodefense work), and an unnamed prime on a grant sub-award to the Executive Office of the Governor of Delaware for laboratory genetic analysis products and services. Illumina does not report subcontractor engagement in the SCI dataset (0% average sub-hours share), indicating the vendor builds its own delivery teams for service contracts and operates primarily as a supplier of proprietary hardware and consumables rather than as a labor-intensive service provider.

Federal grant footprint is minimal and not separately characterized in the source; the sub-grant award to Delaware suggests limited participation in grant-funded research support outside the core contract work. The award portfolio is concentrated in NAICS 334516 (Analytical Laboratory Instrument Manufacturing), with 6,109 of 8,680 awards, and PSC Laboratory Equipment and Supplies (4,943 awards), reflecting Illumina's identity as a goods manufacturer rather than a service provider. Top awards date to 2003; the vendor has maintained continuous federal contracting presence over two decades. Illumina holds no SBA certifications (8(a), HUBZone, SDVOSB, WOSB, or other set-asides) across the footprint, competing on commercial capabilities and proprietary technology position alone. The corporate structure includes named subsidiaries Epicentre Technologies Corporation and Affomix Corporation, both registered as for-profit manufacturers, though award activity is attributed to the parent Illumina, Inc. entity.